Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2319-2323

  Chen, Na ^a   Lu, Kang ^a   Li, Peipei ^a   Lv, Xiao ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; Prognosis; pSTAT6

Indexed keywords

IL4 PROTEIN, HUMAN; IL9 PROTEIN, HUMAN; INTERLEUKIN 4; INTERLEUKIN 9; MESSENGER RNA; RECOMBINANT PROTEIN; STAT6 PROTEIN; STAT6 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-4; INTERLEUKIN-9; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84902497949     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Attia MA, Nosair NA, Gawally A, Elnagar G, Elshafey EM. HLA-G Expression as a Prognostic Indicator in B-Cell Chronic Lymphocytic Leukemia. Acta Haematol 2014; 132: 53-58.
2. Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Gattazzo C, Martini V, Trimarco V, Mazzorana M, Bordin L, Semenzato G, Brunati AM. Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. Blood 2014; 123: 875-883.
3. Niu S, Chan R, Berini P, Wang C, Zou S. Morphology and expression status investigations of specific surface markers on B-cell chronic lymphocytic leukemia cells. Microsc Res Tech 2013; 76: 1147-1153.
4. Huang PY, Kohnke P, Belov L, Best OG, Mulligan SP, Christopherson RI. Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. J Pharm Pharm Sci 2013; 16: 231-237.
5. Iova A, Vladareanu AM, Vasile D, Bumbea H. Difficulty in classifying a B cell chronic lymphoproliferative disorder CD5+. Rom J Intern Med 2012; 50: 309-312.
6. Ronchetti D, Mosca L, Cutrona G, Tuana G, Gentile M, Fabris S, Agnelli L, Ciceri G, Matis S, Massucco C, Colombo M, Reverberi D, Recchia AG, Bossio S, Negrini M, Tassone P, Morabito F, Ferrarini M, Neri A. Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med Genomics 2013; 6: 27.
7. Kneitz C, Goller M, Seggewiss R, Yaman A, Serfling E, Tony HP. STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia. Leuk Res 2000; 24: 331-337.
8. Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, Leroy K, Papadopoulou V, Wagner S, Marienfeld R, Brüderlein S, Lennerz JK, Möller P. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget 2013; 4: 1093-1102.
9. Liu X, Tang Z, Zhang Y, Hu J, Li D, Zang G, Yu Y. Lentivirally overexpressed T-bet regulates T-helper cell lineage commitment in chronic hepatitis B patients. Mol Med Rep 2012; 6: 361-366.
10. Kumar V. Innate lymphoid cells: new paradigm in immunology of inflammation. Immunol Lett 2014; 157: 23-37.
11. Tete S, Saggini A, Maccauro G, Rosati M, Conti F, Cianchetti E, Tripodi D, Toniato E, Fulcheri M, Salini V, Caraffa A, Antinolfi P, Frydas S, Pandolfi F, Conti P, Potalivo G, Nicoletti M, Theoharides TC. Interleukin-9 and mast cells. J Biol Regul Homeost Agents 2012; 26: 319-326.
12. Lauder AJ, Jolin HE, Smith P, van den Berg JG, Jones A, Wisden W, Smith KG, Dasvarma A, Fallon PG, McKenzie AN. Lymphomagenesis, hydronephrosis, and autoantibodies result from dysregulation of IL-9 and are differentially dependent on Th2 cytokines. J Immunol 2004; 173: 113-122.
13. Nishimura M, Kakinuma S, Yamamoto D, Kobayashi Y, Suzuki G, Sado T, Shimada Y. Elevated interleukin-9 receptor expression and response to interleukins-9 and-7 in thymocytes during radiation-induced T-cell lymphomagenesis in B6C3F1 mice. J Cell Physiol 2004; 198: 82-90.
14. Glimelius I, Edström A, Amini RM, Fischer M, Nilsson G, Sundström C, Enblad G, Molin D. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006; 76: 278-283.
15. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphomacells. Blood 2006; 108: 2407-2415.
16. Feng LL, Gao JM, Li PP, Wang X. IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-Hodgkin's lymphoma. J Clin Immunol 2011; 31: 1084-1094.
17. Lv X, Feng L, Fang X, Jiang Y, Wang X. Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 2013; 6: 911-916.
18. Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, Shimizu N, Tateno M, Harabuchi Y. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005; 11: 8250-8257.
19. Chen N, Lv X, Li P, Lu K, Wang X. Role of high expression of IL-9 in prognosis of CLL. Int J Clin Exp Pathol 2014; 7: 716-721.
20. Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, Janik JE, Jacobson S, Waldmann TA. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117: 1938-1946.
21. Brignull LM, Czimmerer Z, Saidi H, Daniel B, Villela I, Bartlett NW, Johnston SL, Meira LB, Nagy L, Nohturfft A. Reprogramming of lysosomal gene expression by interleukin-4 and Stat6. BMC Genomics 2013; 14: 853.
22. Casaca VI, Illi S, Klucker E, Ballenberger N, Schedel M, von Mutius E, Kabesch M, Schaub B. STAT6 polymorphisms are associated with neonatal regulatory T cells and cytokines and atopic diseases at 3 years. Allergy 2013; 68: 1249-1258.
23. Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, Lu Y, Kong S. Increased interleukin-9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 2013; 7: 1031-1037.
24. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC. Acute lymphoblastic leukemia-associated JA-K1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009; 284: 6773-6781.
25. Tao L, Liu J, Li Z, Dai X, Li S. Role of the JAK-STAT pathway in proliferation and differentiation of human hypertrophic scar fibroblasts induced by connective tissue growth factor. Mol Med Rep 2010; 3: 941-945.
26. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008; 27: 1511-1519.
27. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012; 1247: 56-68.
28. Chen N, Wang X. Role of IL-9 and STATs in hematological malignancies (Review). Oncol Lett 2014; 7: 602-610.